

Media Release

Zug, 17 May 2019

**HBM Healthcare Investments reports a profit of CHF 209 million for the 2018/2019 financial year; Further increase of the proposed cash distribution by 50 cents to a total of CHF 7.50 per share.**

With an increase in net assets of 18 percent, HBM Healthcare Investments looks back upon another successful financial year. With a profit of CHF 209 million, the 2018/2019 year-end result seamlessly carries forward the achievements of previous years. Cumulated profits over the past six years exceed CHF 1 billion. During the same period, net asset value (NAV), including distributions, per share more than trebled, while the share price almost quadrupled. This steady growth in value has resulted in a significantly stronger shareholder base. The proposed cash distribution of CHF 7.50 represents an increase of 50 cents compared to the previous year.

Innovations in the healthcare market are the main driving force behind investment success. The potential is far from exhausted. The need for new therapies remains considerable, despite the current record level of new drug approvals. HBM Healthcare Investments is grasping the opportunities presented by these developments, having invested CHF 141 million in private companies during the year under review, including 15 new holdings. The Asian allocation has been increased to 22 percent. The portfolio remains balanced, well diversified, and partially hedged.

Many private portfolio companies are performing very well. Both private and public portfolio companies are expected to publish significant study results and approval decisions during the new financial year, with the corresponding effect on their value.

**Review of the 2018/2019 financial year**

Net asset value (NAV) per share rose by 18 percent, while the share price advanced by 22 percent. Profit for the year as at the end of March 2019 stood at CHF 209 million. Investment activities achieved a net CHF 266 million contribution to profits, with CHF

153 million generated by private companies and funds, CHF 101 million by public companies, and CHF 12 million by other assets.

In the portfolio of private companies, the IPOs of Y-mAbs Therapeutics (profit contribution of CHF 50 million) and Principia Biopharma (CHF 20 million) released added value. In addition, the following investments were revalued due to higher valuations in financing rounds with third-party investors: Cathay Industrial Biotech (CHF 38 million), Neurelis (CHF 20 million), SAI Life Sciences (CHF 11 million) and 1mg (CHF 8 million). These revaluations demonstrate the successful operating performance of the companies concerned.

In the portfolio of fund investments, the value of our largest holding – in WuXi Healthcare Ventures II (profit contribution of CHF 11 million) – increased significantly as Chinese oncology firm CStone Pharmaceuticals went public in Hong Kong.

HBM Healthcare Investments also benefited from three takeovers in the portfolio of public companies. Former private company ARMO BioSciences (profit contribution of CHF 22 million) was acquired by Eli Lilly, Tesaro Pharmaceuticals (CHF 8 million) by GlaxoSmithKline, and AveXis (CHF 8 million) by Novartis. HBM Healthcare Investments acquired its holding in the latter two of these companies via the stock market.

The reporting year also brought significant increases in the value of our holdings in Ultragenyx (profit contribution of CHF 20 million), Argenx (CHF 19 million), BioArctic (CHF 17 million) and Ra Pharma (CHF 16 million).

The partial market hedge of the public portfolio had no effect on net income during the financial year. Two-thirds of the hedge was closed out following the sharp drop in share prices towards the end of the fourth calendar quarter of 2018, and increased slightly once again after the sharp counter-movement in the first quarter of 2019. Around 13 percent of the public portfolio was hedged as at the end of March 2019.

Management fees of about CHF 17 million are in line with the rise in net assets, while the Company's other administration costs remain unchanged at around CHF 3 million. In addition, in view of the increase in value achieved during the reporting year, which significantly exceeds the previous highwater mark, a performance fee of CHF 31.9 million is due to the investment advisor. The Board of Directors will receive variable compensation of CHF 2.0 million.

## **Higher cash dividend**

The Board of Directors will propose to the Ordinary Shareholders' Meeting that the cash dividend be increased by CHF 0.50 to CHF 7.50, in the form of a withholding tax-exempt par value repayment. This corresponds to a distribution yield of 4.4 percent, which thus remains at the upper end of the target bandwidth of 3 to 5 percent.

## **CHF 141 million for private companies**

HBM Healthcare Investments invested a total of CHF 114 million in 15 private companies during the year under review. Of this, CHF 87 million has already been paid in. Investment tranches of CHF 27 million remain outstanding. Further, CHF 27 million was dedicated to follow-on investments in existing private companies.

In the final quarter of the financial year HBM Healthcare Investments made a new investment of USD 12 million in the US company SpringWorks Therapeutics. SpringWorks has a pipeline of compounds for the treatment of rare forms of cancer in late-stage clinical development.

Other major new investments during the reporting year included Jianke Pharmaceutical (USD 15 million, an online healthcare service platform), Principia Therapeutics (USD 12 million, immunology and oncology), Turning Point Therapeutics (USD 10 million, oncology), Sublimity Therapeutics (EUR 8 million, compound to treat chronic inflammation of the colon), Sphingotec (EUR 9 million, diagnosis and treatment monitoring in the case of acute renal injury, heart failure and septic shock), Adrenomed (EUR 6 million, antibodies to treat patients with septic shock), Galecto Biotech (EUR 7 million, idiopathic pulmonary fibrosis), and iTeos Therapeutics (EUR 5 million, immuno-oncology).

Smaller investments of USD 3 to 5 million were also made in six further companies.

## **Broadly diversified portfolio**

HBM Healthcare Investments continues to provide a portfolio that is well balanced in terms of diversification, liquidity, and geographical reach. The largest holding at the end of March 2019 accounts for around 9 percent of net assets, and the ten largest investments together make up one third of the portfolio overall. The relative proportion of individual investments may nonetheless rise sharply at times, in connection with the revaluation at a financing round or an IPO, for example.

The Company's assets of CHF 1.5 billion are also well balanced. They were composed as follows as at the end of March 2019: 26 percent private companies, 9 percent funds and 45 percent public companies (39 percent when the hedge is taken into account). Cash and cash equivalents account for 17 percent (11 percent if all market hedge positions are closed out). At around 7 percent, non-current financial liabilities remain at a very moderate level.

The portfolio is also broadly diversified geographically, with 58 percent of investments in the world's largest healthcare market, the US, 20 percent in Europe and 22 percent in Asia, HBM Healthcare Investments is positioned to engage in opportunities around the globe.

## **Positive portfolio outlook**

Many private portfolio companies are performing very well. In accordance with HBM Healthcare Investments policies, these investments are conservatively valued, and should generate considerable added value in the event of an IPO or trade sale.

Both private and public portfolio companies (such as Neurelis and Harmony Biosciences) are expected to publish significant study results and approval decisions during the new financial year, with the corresponding effect on their value. Here, too, HBM Healthcare Investments anticipates a range of positive publications, most of which will release value potential or open up strategic opportunities.

In view of the relatively low level of visibility on the financial markets, the Company will continue to keep a critical eye on general market trends, and will reduce its exposure to listed stocks, or increase the hedge, as necessary.

HBM Healthcare Investments has a high conviction that its balanced, high-quality portfolio continues to offer more value-creation potential.

In the appendix to this media release you will find the balance sheet and income statement in accordance with IFRS, the portfolio details and an overview of the consolidated financials including a translation to the IFRS Financial Statements. The detailed Annual Report will be published on 31 May 2019 and will be available on the Company's website from that date onwards.

## **Contact**

For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at [andreas.wicki@hbmhealthcare.com](mailto:andreas.wicki@hbmhealthcare.com)

## **About HBM Healthcare Investments**

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

## **Disclaimer**

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (Wertpapierprospektgesetz). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

## Balance Sheet

<b>Balance sheet</b> (CHF 000)	<b>31.3.2019</b>	<b>31.3.2018</b>
<b>Assets</b>		
<b>Current assets</b>		
Cash and cash equivalents	4 703	6 522
Receivables	26	37
<b>Total current assets</b>	<b>4 729</b>	<b>6 559</b>
<b>Non-current assets</b>		
Investment in subsidiary	1 417 427	1 253 924
<b>Total non-current assets</b>	<b>1 417 427</b>	<b>1 253 924</b>
<b>Total assets</b>	<b>1 422 156</b>	<b>1 260 483</b>
<b>Liabilities</b>		
<b>Current liabilities</b>		
Liability from performance fee	2 034	1 018
Other liabilities	2 457	2 333
<b>Total current liabilities</b>	<b>4 491</b>	<b>3 351</b>
<b>Non-current liabilities</b>		
Financial liabilities	99 401	99 236
<b>Total non-current liabilities</b>	<b>99 401</b>	<b>99 236</b>
<b>Shareholders' equity</b>		
Share capital	396 720	411 840
Treasury shares	– 402	– 10 048
Capital reserve	142 093	185 318
Retained earnings	779 853	570 786
<b>Total shareholders' equity</b>	<b>1 318 264</b>	<b>1 157 896</b>
<b>Total liabilities and shareholders' equity</b>	<b>1 422 156</b>	<b>1 260 483</b>
Number of outstanding shares (in 000)	6 957	6 957
Net asset value (NAV) per share (CHF)	189.48	166.43

## Comprehensive Income

<b>Statement of comprehensive income for the financial year ended 31 March</b> (CHF 000)	<b>2018/2019</b>	<b>2017/2018</b>
Dividend income from investment in subsidiary	52 000	60 000
Net change in value of investment in subsidiary	163 503	61 090
<b>Result from investment activities</b>	<b>215 503</b>	<b>121 090</b>
Personnel expenses	– 2 923	– 1 908
Other operating expenses	– 1 079	– 871
<b>Result before interest and taxes</b>	<b>211 501</b>	<b>118 311</b>
Financial expenses	– 2 435	– 2 438
Financial income	1	1
Income taxes	0	0
<b>Net result for the year</b>	<b>209 067</b>	<b>115 874</b>
<b>Comprehensive result</b>	<b>209 067</b>	<b>115 874</b>
Number of outstanding shares, time-weighted (in 000)	6 957	7 001
Basic earnings per share (CHF)	30.05	16.55

As the Company does not have options or similar instruments outstanding, diluted earnings per share are identical to basic earnings per share.

## Investment in Subsidiary

The fair value of the investment in the Subsidiary HBM Healthcare Investments (Cayman) Ltd. developed as follows in the year under review:

Development fair value investment (CHF 000)	2018/2019	2017/2018
<b>Fair value at the beginning of financial year</b>	<b>1 253 924</b>	<b>1 192 834</b>
Increase in value, gross	215 503	121 090
Dividend payment to parent company	– 52 000	– 60 000
<b>Fair value at the end of financial year</b>	<b>1 417 427</b>	<b>1 253 924</b>

Net assets of the investment in the Subsidiary comprised the following as at the balance sheet date:

Composition net assets (CHF 000)	31.3.2019	31.3.2018
Cash and cash equivalents	263 702	213 551
Receivables	525	393
Investments		
Private companies	409 571	288 365
Funds	132 574	125 579
Public companies	688 232	749 960
Shares of parent company	15 696	7 403
Financial instruments	259	3 121
Other financial assets	31 978	29 740
<b>Total assets</b>	<b>1 542 537</b>	<b>1 418 112</b>
Financial instruments	– 92 224	– 147 628
Liability from performance fee	– 31 871	– 15 942
Other current liabilities	– 1 015	– 618
<b>Total net assets at fair value</b>	<b>1 417 427</b>	<b>1 253 924</b>

During the reporting period, the net assets of the investment in the Subsidiary have developed as follows:

Change in net assets at fair value (CHF 000)	2018/2019	2017/2018
Net result on investments	253 320	190 868
Dividend income	686	140
Net result from financial instruments	59	– 33 938
Net result from other financial assets	9 357	– 6 515
Net result from shares of parent company	2 487	2 042
<b>Result from investing activities</b>	<b>265 909</b>	<b>152 597</b>
Management fee	– 17 322	– 14 229
Performance fee	– 31 871	– 15 942
Personnel and other operating expenses	– 1 282	– 1 369
Financial result	69	33
<b>Increase in value, gross</b>	<b>215 503</b>	<b>121 090</b>
Dividend payment to parent company	– 52 000	– 60 000
<b>Net change in value of investment</b>	<b>163 503</b>	<b>61 090</b>



## Details on Investments

Group Financial Statements IFRS

Private companies	Domicile	Investment currency	Amount disbursed 31.3.2018	Changes in reporting period	Amount disbursed 31.3.2019	Fair value 31.3.2019	Ownership 31.3.2019	Fair value 31.3.2019	Fair value 31.3.2018
		IC	IC million	IC million	IC million	IC million	%	CHF 000	CHF 000
Cathay Industrial Biotech	CN	USD	28.0		28.0	125.7	7.9	125 101	87 292
Neurelis	US	USD	8.3	9.5	17.8	37.7	15.0	37 522	7 870
Harmony Biosciences	US	USD	30.0		30.0	32.6	7.6	32 452	31 109
Amicus	CH	EUR	20.0		20.0	20.0	29.0	22 329	23 514
1mg	IN	INR	515.7	357.1	872.8	1 452.4	10.5	20 899	7 543
SAI Life Sciences	IN	INR	256.4	192.6	449.0	1 343.9	5.3	19 339	6 019
Jianke Pharmaceutical	CN	USD	0.0	14.9	14.9	14.9	3.3	14 803	0
Westmed Holding	US	USD	7.0		7.0	12.4	25.2	12 374	11 862
SpringWorks Therapeutics	US	USD	0.0	12.0	12.0	12.0	3.6	11 942	0
Turning Point Therapeutics	US	USD	0.0	10.0	10.0	10.0	3.3	9 952	0
Vascular Dynamics	US	USD	10.0	1.3	11.3	9.7	13.1	9 657	9 505
FarmaLatam	PA	USD	7.7	1.2	8.9	8.9	70.2	8 830	7 320
Valcare	US	USD	3.5	0.8	4.3	7.1	8.4	7 017	3 339
ConnectRN	US	USD	1.5	2.5	4.0	6.6	20.2	6 557	1 431
Shape Memory Medical	US	USD	3.0	3.0	6.0	6.0	17.4	5 971	2 862
Sphingotec	DE	EUR	0.0	4.5	4.5	4.5	7.1	5 029	0
Cardialen	US	USD	0.0	5.0	5.0	5.0	17.8	4 976	0
Galera Therapeutics	US	USD	0.0	5.0	5.0	5.0	2.0	4 976	0
Forbuis (Formation Biologics)	CA	CAD	6.5		6.5	6.5	9.6	4 809	4 771
Corvidia Therapeutics	US	USD	0.0	4.0	4.0	4.0	3.1	3 981	0
Vitaeris	CA	USD	3.0		3.0	4.0	18.7	3 981	3 816
Sublimity Therapeutics	IE	EUR	0.0	3.5	3.5	3.5	7.1	3 960	0
Complexa	US	USD	2.9	1.1	4.0	4.0	4.7	3 933	2 771
Shriji Polymers	IN	INR	201.0		201.0	268.2	3.0	3 860	3 163
Nuance Biotech	CN	USD	0.0	4.0	4.0	3.7	3.7	3 696	0
Galecto Biotech	DK	EUR	0.0	3.2	3.2	3.2	4.3	3 552	0
Cure Everlife Holdings	MU	USD	0.0	3.0	3.0	3.0	7.8	2 986	0
Everest Medicines	CN	USD	0.0	3.0	3.0	3.0	1.0	2 986	0
BaseHealth	US	USD	2.5		2.5	2.5	6.3	2 488	2 385
iTeos Therapeutics	BE	EUR	0.0	1.6	1.6	1.6	3.8	1 801	0
Amphora Medical	US	USD	2.2	0.4	2.6	0.7	5.5	725	2 074
Adrenomed <sup>1)</sup>	DE	EUR	0.0	0.3	0.3	0.3	8.7	381	0
Iconic Therapeutics	US	USD	7.5		7.5	0.0	0.8	0	1 789
TandemLife (Cardiac Assist)	US	USD	4.4	-4.4	0.0	0.0	0.0	0	31 148
Others								6 706	8 405
<b>Total private companies</b>								<b>409 571</b>	<b>259 988</b>

1) So far only the nominal capital has been paid.

Funds	Investment currency	Total commitment	Payments in reporting period	Repayments in reporting period	Cumulative payments 31.3.2019	Cumulative repayments 31.3.2019	Fair value 31.3.2019	Fair value 31.3.2019	Fair value 31.3.2018
	IC	IC million	IC million	IC million	IC million	IC million	IC million	CHF 000	CHF 000
WuXi Healthcare Ventures II	USD	20.0	4.2		17.2	0.6	28.5	28 388	12 974
HBM BioCapital II <sup>1)</sup>	EUR	42.0	4.2	5.6	41.2	9.2	20.6	23 009	30 585
MedFocus Fund II	USD	26.0			16.0	15.0	18.8	18 740	17 971
6 Dimensions Capital	USD	25.0	3.2	0.1	16.2	0.1	14.1	13 987	12 243
HBM Genomics	USD	15.0	3.3		12.2	0.0	11.6	11 523	8 137
Tata Capital HBM Fund I	USD	10.0	0.3	4.2	9.4	4.7	8.2	8 177	9 094
BioMedInvest II	CHF	10.0		1.2	10.0	3.0	7.0	7 010	8 840
Hatteras Venture Partners III	USD	10.0			10.0	2.0	5.9	5 853	8 250
BioMedInvest I	CHF	26.0		1.0	26.0	25.6	5.1	5 092	6 994
Galen Partners V	USD	10.0	0.1	1.2	10.4	8.8	4.9	4 865	5 168
Nordic Biotech	DKK	31.0			31.0	221.7	10.6	1 578	2 781
BioVeda China IV	USD	5.0	1.4		1.4	0.0	1.3	1 260	0
C-Bridge Capital IV	USD	10.0	1.4	0.1	1.4	0.1	1.2	1 242	0
Others								1 850	2 542
<b>Total funds</b>								<b>132 574</b>	<b>125 579</b>

1) The fair value of EUR 20.6 million takes into account the fund's cumulative management fees of EUR 5.2 million. This amount has

been reimbursed in full to HBM Healthcare so that fees are not levied twice.



Public companies	Investment currency	Balance 31.3.2018	Changes in reporting period	Balance 31.3.2019	Share price 31.3.2019	Ownership 31.3.2019	Fair value 31.3.2019	Fair value 31.3.2018
	IC	Number of shares	Number of shares	Number of shares	IC	%	CHF 000	CHF 000
Y-mAbs Therapeutics <sup>1)P)</sup>	USD	2 486 095	372 460	2 858 555	26.21	8.4	74 563	22 176
Vectura Group	GBP	63 002 869	-21 422 945	41 579 924	0.71	6.3	38 513	65 410
Pacira Pharmaceuticals <sup>P)</sup>	USD	1 100 000	-149 738	950 262	38.06	2.3	35 993	32 689
Galapagos	EUR	300 000	-7 858	292 142	103.90	0.5	33 887	28 676
Ultragenyx Pharmaceutical	USD	500 000	-50 000	450 000	69.36	0.8	31 062	24 322
Principia Biopharma <sup>1)P)</sup>	USD	0	833 923	833 923	34.00	3.5	28 217	0
Zogenix	USD	400 000	113 219	513 219	55.01	1.2	28 097	15 283
Immunomedics	USD	1 400 000	-88 510	1 311 490	19.21	0.7	25 073	19 513
Alnylam Pharmaceuticals	USD	0	265 616	265 616	93.45	0.3	24 703	0
Argenx (ADR)	USD	250 542	-66 542	184 000	124.84	0.5	22 860	19 227
Argenx	EUR	250 000	-64 000	186 000	110.00	0.5	22 842	19 164
Esperion Therapeutics	USD	400 000	171 257	571 257	40.15	2.1	22 826	27 601
RA Pharmaceuticals	USD	750 000	96 958	846 958	22.40	2.0	18 881	3 799
Acadia Pharmaceuticals	USD	700 000	0	700 000	26.85	0.5	18 705	15 005
AnaptysBio <sup>P)</sup>	USD	200 000	46 175	246 175	73.05	0.9	17 897	19 858
ObsEva (ADS) <sup>P)</sup>	USD	2 313 330	-926 732	1 386 598	12.79	3.1	17 649	29 782
Arena Pharmaceuticals	USD	250 000	115 000	365 000	44.83	0.7	16 284	9 421
Amicus Therapeutics	USD	844 784	214 277	1 059 061	13.60	0.5	14 334	12 121
Retrophin	USD	433 952	153 197	587 149	22.63	1.4	13 223	9 257
Divis Laboratories	INR	608 000	-135 700	472 300	1 703.10	0.2	11 575	9 695
Coherus Biosciences	USD	577 442	240 000	817 442	13.64	1.2	11 096	6 087
Nicox	EUR	1 673 304	0	1 673 304	5.64	5.6	10 527	17 844
Idorsia	CHF	0	600 000	600 000	17.52	0.5	10 512	0
Uniqure	USD	0	176 822	176 822	59.65	0.5	10 497	0
Albireo Pharma	USD	200 000	119 800	319 800	32.21	2.7	10 251	6 214
Arrowhead Pharmaceuticals	USD	0	550 000	550 000	18.35	0.6	10 044	0
Spring Bank Pharmaceuticals	USD	258 736	400 000	658 736	10.49	4.0	6 877	3 796
Beigene	HKD	0	700 000	700 000	77.20	0.1	6 851	0
Beigene (ADR)	USD	0	50 000	50 000	132.00	0.1	6 568	0
Jubilant Life Sciences	INR	0	608 006	608 006	664.80	0.4	5 816	0
Assembly Biosciences	USD	0	290 727	290 727	19.69	1.1	5 697	0
Dermira	USD	0	400 000	400 000	13.55	0.8	5 394	0
Xenon Pharmaceuticals	USD	0	521 789	521 789	10.16	2.0	5 276	0
Myokardia	USD	0	100 000	100 000	51.99	0.2	5 174	0
Collectis (ADR)	USD	0	269 363	269 363	18.34	0.6	4 916	0
Nabriva Therapeutics	USD	2 334 007	-500 000	1 834 007	2.44	2.6	4 454	11 200
Viking Therapeutics	USD	0	400 000	400 000	9.94	0.6	3 957	0
Paratek Pharmaceuticals <sup>P)</sup>	USD	895 000	-187 552	707 448	5.36	2.2	3 774	11 100
Rubius Therapeutics	USD	0	207 592	207 592	18.10	0.3	3 739	0
Alimera Sciences	USD	3 500 000	0	3 500 000	1.06	4.9	3 692	3 439
Solara Active	INR	0	611 806	611 806	418.45	2.5	3 684	0
Hansa Medical	SEK	0	150 000	150 000	225.00	0.4	3 615	0
Laurus Labs	INR	501 698	104 948	606 646	399.55	0.6	3 488	3 690
Vicore Pharma	SEK	1 084 166	857 548	1 941 714	16.30	4.6	3 390	2 077
Aptinyx <sup>1)P)</sup>	USD	790 873	-57 322	733 551	4.05	2.2	2 957	6 201
ARMO BioSciences <sup>2)P)</sup>	USD	1 591 540	-1 591 540	0	n/a	0.0	0	56 801
Tesaro <sup>2)</sup>	USD	250 000	-250 000	0	n/a	0.0	0	13 628
AveXis <sup>2)</sup>	USD	100 000	-100 000	0	n/a	0.0	0	11 790
Others							18 802	241 471
<b>Total public companies</b>							<b>688 232</b>	<b>778 337</b>
<b>Total investments</b>							<b>1 230 377</b>	<b>1 163 904</b>

P) The position originates from the private companies portfolio.

1) The companies went public on NASDAQ in the current reporting period. The investments were listed under private companies in previous reports with the exception of Principia Biopharma.

2) The company was acquired by another company during the 2018/2019 financial year. HBM Healthcare sold all of its shares.

## Balance Sheet

Balance sheet (CHF 000)	Consolidated Financials <sup>2)</sup> 31.3.2019 (unaudited)	Translation <sup>3)</sup>	IFRS Group Finan- cial Statements 31.3.2019 (audited)
<b>Assets</b>			
<b>Current assets</b>			
Cash and cash equivalents	268 405	- 263 702	4 703
Receivables	551	- 525	26
Financial instruments	259	- 259	0
<b>Total current assets</b>	<b>269 215</b>	<b>- 264 486</b>	<b>4 729</b>
<b>Non-current assets</b>			
Investments	1 230 377	- 1 230 377	0
Other financial assets	31 978	- 31 978	0
Investment in subsidiary	0	1 417 427	1 417 427
<b>Total non-current assets</b>	<b>1 262 355</b>	<b>155 072</b>	<b>1 417 427</b>
<b>Total assets</b>	<b>1 531 570</b>	<b>- 109 414</b>	<b>1 422 156</b>
<b>Liabilities</b>			
<b>Current liabilities</b>			
Financial instruments	92 224	- 92 224	0
Liability from performance fee	33 905	- 31 871	2 034
Other liabilities	3 472	- 1 015	2 457
<b>Total current liabilities</b>	<b>129 601</b>	<b>- 125 110</b>	<b>4 491</b>
<b>Non-current liabilities</b>			
Financial liabilities	99 401	0	99 401
<b>Total non-current liabilities</b>	<b>99 401</b>	<b>0</b>	<b>99 401</b>
<b>Shareholders' equity</b>			
Share capital	396 720	0	396 720
Treasury shares	- 15 744	15 342	- 402
Capital reserve	149 182	- 7 089	142 093
Retained earnings	772 410	7 443	779 853
<b>Total shareholders' equity</b>	<b>1 302 568</b>	<b>15 696</b>	<b>1 318 264</b>
<b>Total liabilities and shareholders' equity</b>	<b>1 531 570</b>	<b>- 109 414</b>	<b>1 422 156</b>
Number of outstanding shares (in 000)	6 864	93	6 957
Net asset value (NAV) per share (CHF)	189.77		189.48

- 1) Details on the individual items can be found in the notes to the audited IFRS Group Financial Statements of the annual report.
- 2) Consolidated financials of the HBM Healthcare Group with full consolidation of the subsidiary HBM Healthcare Investments (Cayman) Ltd. and its subsidiary HBM Private Equity India Ltd, Republic of Mauritius.
- 3) Reconciliation to the audited IFRS Group Financial Statements. Based on IFRS 10, the subsidiary is no longer consolidated, but

is valued individually at fair value through profit and loss. The differences in equity and net profit for the year result from the shares of the parent company held by the subsidiary. In the consolidated financial statements, these are deducted from equity at their acquisition cost. In the IFRS Group Financial Statements, they are valued at fair value through profit and loss by the subsidiary.

## Comprehensive Income

Statement of comprehensive income for the financial year ended 31 March (CHF 000)	Consolidated Financials <sup>2)</sup> 2018/2019 (unaudited)	IFRS Group Finan- cial Statements 2018/2019 (audited)	
		Translation <sup>3)</sup>	
Net result on investments	253 320	– 253 320	0
Dividend income	686	– 686	0
Net result from financial instruments	59	– 59	0
Net result from other financial assets	9 357	– 9 357	0
Dividend income from investment in subsidiary	0	52 000	52 000
Net change in value of investment in subsidiary	0	163 503	163 503
<b>Result from investment activities</b>	<b>263 422</b>	<b>– 47 919</b>	<b>215 503</b>
Management fee	– 17 322	17 322	0
Performance fee	– 31 871	31 871	0
Personnel expenses	– 3 802	879	– 2 923
Other operating expenses	– 1 482	403	– 1 079
<b>Result before interest and taxes</b>	<b>208 945</b>	<b>2 556</b>	<b>211 501</b>
Financial expenses	– 2 435	0	– 2 435
Financial income	70	– 69	1
Income taxes	0	0	0
<b>Net result for the year</b>	<b>206 580</b>	<b>2 487</b>	<b>209 067</b>
<b>Comprehensive result</b>	<b>206 580</b>	<b>2 487</b>	<b>209 067</b>
Number of outstanding shares, time-weighted (in 000)	6 892	65	6 957
Basic earnings per share (CHF)	29.97		30.05

For the footnotes, see previous page.